PSMA PET scanning can improve decision making for prostate cancer treatment

bySociety of Nuclear MedicineHeat map of prostate bed PSMA PET recurrences distribution in the miTr N0 Mo cohort (n=127 patients) mapped on a template patient’s anatomy (the green contour repres

Updated on: December 17,2023

PSMA PET scanning can improve decision making for prostate cancer treatment

bySociety of Nuclear MedicineHeat map of prostate bed PSMA PET recurrences distribution in the miTr N0 Mo cohort (n=127 patients) mapped on a template patient’s anatomy (the green contour repres

Updated on:December 17,2023

Novel subtype of nasopharyngeal carcinoma and Epstein-Barr virus–associated immune suppression discovered

Updated on: December 21,2023

Novel subtype of nasopharyngeal carcinoma and Epstein-Barr virus–associated immune suppression discovered

Updated on:December 21,2023

Study identifies skin microbiome as a factor in stem cell transplants

Study identifies skin microbiome as a factor in stem cell transplantsbyMedical University of ViennaCredit: AI-generated imageOrgan damage occurs in up to 70% of patients in the first few months

Updated on: October 30,2023

Study identifies skin microbiome as a factor in stem cell transplants

Study identifies skin microbiome as a factor in stem cell transplantsbyMedical University of ViennaCredit: AI-generated imageOrgan damage occurs in up to 70% of patients in the first few months

Updated on:October 30,2023

Tumor Profiling Studies Illuminate Nuances Across Malignancies

November 21, 2022Megan HollaschMolecular and immune landscapes for solid tumors are constantly evolving as precision medicine techniques become more sensitive and next-generation sequencing methods ar

Updated on: October 17,2023

Tumor Profiling Studies Illuminate Nuances Across Malignancies

November 21, 2022Megan HollaschMolecular and immune landscapes for solid tumors are constantly evolving as precision medicine techniques become more sensitive and next-generation sequencing methods ar

Updated on:October 17,2023

Radiotherapy for ductal in situ carcinoma ups mortality risk in invasive second breast cancer

(HealthDay)—For women with primary ductal carcinoma in situ (DCIS), use of radiotherapy (RT) is associated with increased rates of breast cancer-specific mortality for those women who subsequently dev

Updated on: December 22,2023

Radiotherapy for ductal in situ carcinoma ups mortality risk in invasive second breast cancer

(HealthDay)—For women with primary ductal carcinoma in situ (DCIS), use of radiotherapy (RT) is associated with increased rates of breast cancer-specific mortality for those women who subsequently dev

Updated on:December 22,2023

New study reveals how blood cancer cells escape the immune system's natural killer cells

byUniversity of HelsinkiGraphical abstract. Credit:Immunity(2023). DOI: 10.1016/j.immuni.2023.11.008The advent of T-cell therapies, where cells of the immune system are directed towa

Updated on: January 26,2024

New study reveals how blood cancer cells escape the immune system's natural killer cells

byUniversity of HelsinkiGraphical abstract. Credit:Immunity(2023). DOI: 10.1016/j.immuni.2023.11.008The advent of T-cell therapies, where cells of the immune system are directed towa

Updated on:January 26,2024

ICI-Treated Synchronous mRCC Is Associated With Negative Survival Outcomes

July 17, 2023Ashling WahnerPatients with synchronous metastatic renal cell carcinoma who received first-line immunotherapy had worse survival outcomes compared with those with metachronous metastatic

Updated on: October 15,2023

ICI-Treated Synchronous mRCC Is Associated With Negative Survival Outcomes

July 17, 2023Ashling WahnerPatients with synchronous metastatic renal cell carcinoma who received first-line immunotherapy had worse survival outcomes compared with those with metachronous metastatic

Updated on:October 15,2023

Frontline Immunotherapy, Delayed Nephrectomy May Allow for Improved Disease Control in mRCC

July 14, 2023Caroline SeymourNeoadjuvant immunotherapy–based combinations led to reductions in tumor size and pathologic necrosis at the time of cytoreductive nephrectomy in patients with metastatic r

Updated on: October 12,2023

Frontline Immunotherapy, Delayed Nephrectomy May Allow for Improved Disease Control in mRCC

July 14, 2023Caroline SeymourNeoadjuvant immunotherapy–based combinations led to reductions in tumor size and pathologic necrosis at the time of cytoreductive nephrectomy in patients with metastatic r

Updated on:October 12,2023

MDNA11 Generates Activity, Safety in Advanced Solid Tumors

August 9, 2023Chris RyanTreatment with the long-acting interleukin-2 superkine led to durable tumor control and no dose-limiting toxicities in patients with advanced solid tumors, according to data fr

Updated on: October 12,2023

MDNA11 Generates Activity, Safety in Advanced Solid Tumors

August 9, 2023Chris RyanTreatment with the long-acting interleukin-2 superkine led to durable tumor control and no dose-limiting toxicities in patients with advanced solid tumors, according to data fr

Updated on:October 12,2023

Study points to new possibilities for treating lung cancer patients

by Birgitte Svennevig,University of Southern DenmarkAn EMT-centric investigation of metabolic processes in a comprehensive lung cancer transcriptome profiles collection identified an inverse ass

Updated on: May 25,2024

Study points to new possibilities for treating lung cancer patients

by Birgitte Svennevig,University of Southern DenmarkAn EMT-centric investigation of metabolic processes in a comprehensive lung cancer transcriptome profiles collection identified an inverse ass

Updated on:May 25,2024

​Nature: Multiple Breakthroughs in Vaccine Technology

Recently, Nature has successively published groundbreaking vaccine research results, attracting widespread attention.

Updated on: February 18,2025

​Nature: Multiple Breakthroughs in Vaccine Technology

Recently, Nature has successively published groundbreaking vaccine research results, attracting widespread attention.

Updated on:February 18,2025

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

August 29, 2017Jason HarrisPembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.Na

Updated on: October 24,2023

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

August 29, 2017Jason HarrisPembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.Na

Updated on:October 24,2023